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Background: The changes in inspiratory capacity (IC) over time in chronic obstructive pulmonary disease (COPD)
patients are unknown. The Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFTW) trial
included IC measurements.
Methods: IC analysis from UPLIFTW (N = 5992) was performed at 1 and 6 months, and every 6 months through
4 years. Annualized rate of decline in pre- and post-bronchodilator IC and mean differences at each time point
were analyzed by mixed-effects models. The relationships between baseline IC and exacerbation rate and mortality
were explored using Cox regression analysis.
Results: Baseline characteristics: age, 65 years; 75% men; post-bronchodilator forced expiratory volume in 1 second,
1.32 L (48% predicted); pre- and post-bronchodilator IC, 2.03 and 2.33 L. Mean IC rate of decline (mL/year) was 34 ±
2 (1.7% of baseline) and 50 ± 3 (2.1% of baseline) pre- and post-bronchodilator, respectively, without significant
between-group differences. Morning pre-bronchodilator (trough) IC improved with tiotropium versus placebo:
124 mL (1 month), 103 mL (1 year), 107 mL (2 years), 98 mL (3 years), and 97 mL (4 years) (all p < 0.001). Post-
bronchodilator improvements were similar between treatment groups. Lower baseline IC values were associated
with reduced time to first exacerbation. For the lowest quartile (n = 1413) the values in months were 14.3 (11.7–
17.0) for tiotropium and 10.3 (8.8–11.7) for controls (p < 0.01).
Conclusion: IC declines from approximately 34 to 50 mL/year in patients with stage II to IV COPD. Tiotropium
treatment does not change the IC decline rate but provides 24-hour improvements in IC sustained over the long
term. Trough IC differences suggest that tiotropium provides sustained decrease in end-expiratory lung volume.
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It has been increasingly recognized that lung volumes
have an independent important association with symp-
tom limitations and outcomes, including survival, in
patients with chronic obstructive pulmonary disease
(COPD) [1-5]. As the disease progresses, air trapping
and hyperinflation develop, which worsen during phys-
ical activity and exacerbations. Increases in inspiratory
capacity (IC) are positively associated with exercise dur-
ation and decreased breathlessness during activity [2-4].
The association appears to be stronger than the associ-
ation of forced expiratory volume in 1 second (FEV1)
with these outcomes and therefore represents an* Correspondence: bcelli@copdnet.org
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reproduction in any medium, provided the orimportant surrogate of the functional impact of COPD
on patient-reported outcomes.
While the annualized rate of decline in FEV1 has been
well studied, there is no information regarding the rate
of change in IC in patients with COPD [6-14]. Few stud-
ies have incorporated long-term evaluations of lung
function beyond FEV1 and forced vital capacity (FVC)
and none have reported on the rate of decline in IC.
The Understanding Potential Long-term Impacts on
Function with Tiotropium (UPLIFTW) trial is a 4-year,
randomized, double-blind, placebo-controlled trial of
tiotropium 18 μg daily in patients with COPD who were
permitted to use all respiratory medications throughout
the trial, other than inhaled anticholinergics [13]. In
UPLIFTW, the IC was measured during the pre- and
post-bronchodilator slow vital capacity (SVC) maneuvers. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ducted the following analyses on the UPLIFTW data:
first, we investigated changes in IC over time in patients
with COPD; second, we evaluated the effect of tiotro-
pium (compared with control) on trough and post-
bronchodilator IC over 4 years; third, we determined the
changes in SVC and forced expiratory volume in 6 sec-
onds (FEV6); finally, we explored the relationship be-
tween IC at baseline and time to first exacerbation, as
well as mortality.
Methods
Study design
The study design details from the UPLIFTW trial have
been published previously [12,13]. UPLIFTW was a ran-
domized, double-blind, placebo-controlled clinical trial
evaluating tiotropium 18 μg daily over 4 years in patients
with COPD. The rates of decline in pre- and post-
bronchodilator FEV1 were the primary endpoints. Abso-
lute values for spirometry over 4 years, exacerbations,
health-related quality of life (according to St George’s
Respiratory Questionnaire [SGRQ]) [15]; only baseline
data reported here), and mortality variables were sec-
ondary outcomes. All maintenance respiratory medica-
tions, except for inhaled anticholinergics, were
permitted. The study had Institutional Review Board ap-
proval and all patients gave written informed consent.
The study was conducted in accordance with the Declar-
ation of Helsinki.
Patients
Patients were included based on a clinical diagnosis of
COPD, post-bronchodilator FEV1 ≤ 70% of predicted,
FEV1/FVC ≤ 0.70, aged ≥ 40 years, and a smoking history
of ≥ 10 pack-years. The major exclusion criteria were as
follows: history of asthma, COPD exacerbation within
4 weeks of screening, prior pulmonary resection, and
supplemental oxygen use > 12 hours per day.
Lung function outcomes
Spirometry was performed according to American Thor-
acic Society (ATS) criteria [16] at baseline, at 30 days’
post-randomization, at every 6 months’ post-
randomization, and at 30 days following the last dose of
study medication. Spirometry was conducted before and
after short-acting bronchodilators (ipratropium 80 μg,
then albuterol 400 μg 60 minutes later). Following
randomization, study drug was administered immedi-
ately prior to short-acting bronchodilators.
Spirometry was performed with the same equipment
at each site using trial-specific customized software.
Results were transmitted for centralized quality assur-
ance assessment (Quantum Research Inc, Louisville,
Colorado, USA). SVC by slow exhalation maneuver wasperformed first, followed by the FVC maneuver. Both
maneuvers were performed three times with up to five
forced expiratory maneuvers permitted in order to ob-
tain three acceptable efforts. The highest acceptable
FEV1 and the highest FVC obtained on any of the three
acceptable efforts were recorded.
IC was measured in maneuvers used to generate the
SVC. All investigators were trained to collect IC and
SVC measurements, and the technique used was stand-
ard and supervised at all centers. A computerized algo-
rithm helped stabilize the end-expiratory signal and
prompted technicians to perform IC and SVC maneu-
vers that met ATS standards. All patients were sitting
and continuous recording was made of the tidal volume.
When patients achieved a tidal volume signal with stable
end-expiratory volume, they were instructed to inspire
as deeply as possible until no more air could be inhaled.
At that point, the patient performed the SVC maneuver
until residual volume was reached. The maneuvers were
repeated after 5 minutes’ rest until three appropriate, re-
producible tracings were obtained. The best IC and SVC
were used for analyses.
Exacerbations, health status, and mortality
Exacerbation data and adverse events were collected at
each clinic visit. For the purpose of this analysis, exacer-
bations were defined by episodes of shortness of breath
and change in the sputum that merited a course of corti-
costeroids or antibiotics (or both) and/or required a visit
to an emergency room or admission to hospital. The
SGRQ was administered at baseline and every 6 months.
Mortality was determined up to Day 1470 after
randomization [13].
Statistical methods
Data from all randomized patients with acceptable pre-
and post-bronchodilator measurements at baseline were
included in this analysis. A mixed-effects model with
repeated measurements analysis of variance was utilized
to determine the rate of change in spirometry variables.
Data sets were restricted to patients with ≥ 3 post-
randomization spirometry test sets for calculation of
annualized rate of decline in FEV1, FVC, and SVC, and
to patients with ≥ 1 post-randomization spirometry test
set for calculation of annualized rate of decline in IC
and FEV6. IC at baseline was divided into approximate
quartiles using the cut points of 1.5, 2.0, and 2.5 L. Haz-
ard ratios for the risk of an exacerbation and for mortal-
ity were calculated using Cox regression.
Results
Study population
The demographics of the UPLIFTW population have
been previously described and are displayed in Table 1
Table 1 Baseline characteristics of patients in the
tiotropium and control groups
Characteristic Tiotropium
(n = 2986)
Control
(n = 3006)
Male, % 75.4 73.9
Age, yearsa 64.5 ± 8.4 64.5 ± 8.5
Body mass indexa 26.0 ± 5.1 25.9 ± 5.1
Smoking status
Current smoker, % 29.3 29.9
Smoking history, pack-yearsa 49.0 ± 28.0 48.4 ± 27.9
SGRQ total score, unitsa 45.7 ± 17.0 46.0 ± 17.2
Respiratory medications, %
Short-acting inhaled
anticholinergicsb
44.9 44.1
Long-acting inhaled anticholinergics 2.0 1.6
Short-acting inhaled β2-agonists
b 68.5 68.1
Long-acting inhaled β2-agonistsb 60.1 60.1
Inhaled corticosteroidsb 61.6 61.9
Oral steroids 8.4 8.3
Theophylline compounds 28.4 28.5
Mucolytics 7.4 6.9
Leukotriene receptor antagonists 3.3 3.1
Supplemental oxygen 2.3 1.9
aMean ± SD. bUsed alone or as a fixed combination.
Abbreviation: SGRQ, St George’s Respiratory Questionnaire.
Table 2 Baseline spirometry (mean± SD) of patients in
the tiotropium and control groups
Tiotropium
(n= 2986)
Control
(n = 3006)
Pre-bronchodilator
FEV1, L 1.10 ± 0.40 1.09 ± 0.40
FEV1, % predicted 39.5 ± 12.0 39.3 ± 11.9
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characterized by the Global Initiative for Chronic Ob-
structive Lung Disease (GOLD) [1], the mean post-
bronchodilator FEV1 was 48 % predicted (Table 2) with
46 %, 44 %, and 9 % stage II, III, and IV disease, respect-
ively. Evaluable measurements of IC at baseline were
available for 5992 patients.FVC, L 2.63 ± 0.81 2.63 ± 0.83
FEV1/FVC 42.4 ± 10.5 42.1 ± 10.5
SVC 2.80 ± 82 2.80 ± 83
IC 2.04 ± 70 2.03 ± 70
FEV6 2.11 ± 62 2.11 ± 62
Post-
bronchodilator
FEV1, L 1.33 ± 0.44 1.32 ± 0.44
FEV1, % predicted 47.7 ± 12.7 47.4 ± 12.6
FVC, L 3.09 ± 0.86 3.09 ± 0.90
FEV1/FVC 43.6 ± 10.8 43.3 ± 10.7
SVC 3.21 ± 88 3.20 ± 90
IC 2.35 ± 75 2.32 ± 77
FEV6 2.49 ± 65 2.48 ± 66
Abbreviations: FEV1, forced expiratory volume in 1 second; FEV6, forced
expiratory volume in 6 seconds; FVC, forced vital capacity; IC, inspiratory
capacity; SD, standard deviation; SVC, slow vital capacity.IC and SVC
Improvements in morning pre-bronchodilator IC were
observed throughout the trial, with the differences
between tiotropium and control ranging from 94 to
125 mL (p < 0.001 at all time points) (Figure 1). Sig-
nificant improvements were also observed for pre-
bronchodilator SVC (between-treatment differences
between 150 and 186 mL, p < 0.001 at all time
points) (Figure 2), and FEV6 (between-treatment dif-
ferences between 131 and 161 mL, p < 0.001 at all
time points) (Figure 3). Differences observed for FVC
were between 170 and 204 mL (p < 0.001) [13].
Pre-bronchodilator IC declined from 32 to 36 mL/year
while post-bronchodilator IC declined from 47 to
52 mL/year, with no differences between treatment
groups (Table 3). The corresponding rates of decline for
SVC were numerically larger, with pre-bronchodilatorvalues between 41 and 47 mL/year and post-
bronchodilator values between 65 and 66 mL/year; cor-
responding values for FEV6 were 40–42 mL/year and
57 mL/year, with no between-treatment differences
(Table 3).
The mean rate of decline in pre-bronchodilator IC was
similar for patients at GOLD stage II (placebo group,
33 mL/year; tiotropium group, 37 mL/year), stage III (34
and 37 mL/year, respectively), and stage IV (20 and
34 mL/year), but increased with the severity of airflow
obstruction for post-bronchodilator IC (GOLD stage II,
41 and 44 mL/year; stage III, 48 and 56 mL/year; stage
IV, 57 and 63 mL/year for the placebo and tiotropium
groups, respectively).
Table 4 illustrates the treatment group pre-
bronchodilator differences at 1, 2, 3, and 4 years for IC,
SVC, FEV6, and FVC. Treatment group differences in IC
appear fairly stable over 4 years. SVC, FEV6, and FVC
showed the largest decline in between-group differences
from Year 3 to Year 4, with minor declines in Year 4.
Associations among values were determined at indi-
vidual time points. The correlations between IC and
FEV1 varied between 0.51 and 0.60 (pre-bronchodilator)
and between 0.45 and 0.54 (post-bronchodilator). The
correlations between IC and FVC varied between 0.57
and 0.66 (pre-bronchodilator) and between 0.55 and
0.63 (post-bronchodilator). The correlations between IC
2.50
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Figure 1 Estimated mean pre- and post-bronchodilator IC in the tiotropium and control groups through 4 years. Abbreviations: IC,
inspiratory capacity.
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tor) and between 0.61 and 0.70 (post-bronchodilator).
Relationship of baseline IC to exacerbations and mortality
The mean (range) of pre-bronchodilator baseline IC by
quartiles were: Q1, 1.15 (0.45–1.50); Q2, 1.76 (1.51–
2.00); Q3, 2.25 (2.01–2.50); Q4, 2.95 (2.51–4.00). Lower
quartiles of IC were associated with a faster time to first
exacerbation within each treatment group (Table 5). Tio-
tropium was associated with a lower risk for an exacer-
bation within each quartile, although the upper limit of
the 95% confidence interval (CI) exceeded one for the
third quartile. Lower quartiles of IC were associated with
a higher risk for a fatal event within each treatment
group (Table 6). While the risk for a fatal event was
reduced with tiotropium in each quartile, in all cases,3.40
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Figure 2 Estimated mean pre- and post-bronchodilator SVC in the tio
slow vital capacity.the 95% CI included one, likely influenced by the rela-
tively low number of events within each quartile
(Table 6).
Discussion
This analysis from the UPLIFTW study offered some
novel findings. Firstly, the pre-bronchodilator IC
declined from 32 to 52 mL/year in patients with COPD
included in the 4-year trial. Secondly, the rate of decline
was similar in patients taking tiotropium compared with
patients taking control plus regular medications, but the
morning IC (trough) was significantly higher in patients
taking tiotropium throughout the study. Thirdly, the
changes in IC were mirrored by the changes in SVC.
Fourthly, lower values of IC at baseline were associated
with higher rates of exacerbations and death.Post-bronchodilator 
difference: 37-61 mL
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Control
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tropium and control groups through 4 years. Abbreviations: SVC,
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Figure 3 Estimated mean pre- and post-bronchodilator FEV6 in the tiotropium and control groups through 4 years. Abbreviations: FEV6,
forced vital capacity in 6 seconds.
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lung volume (EELV) is an important determinant of ex-
ercise limitation and the rate of development of dyspnea
during exercise, as well as a good predictor of survival
[2-5]. Improvement in clinically relevant outcomes such
as increases in exercise endurance time and decreases in
dyspnea have been related more strongly to changes in
EELV than to changes in FEV1 [2-4,17,18].
Furthermore, data from the National Emphysema
Therapy Trial (NETT) have shown improvements in
survival in selected patients who underwent surgical
lung volume reduction compared with patients rando-
mized to medical therapy [19]. Taken together, these
studies strongly support the concept that EELV is an im-
portant determinant of functional capacity and outcome
in patients with COPD.
The IC has been shown to reflect EELV and can be
measured at rest using a spirometer and during exercise
using relatively simple maneuvers [17,20,21]. Until now,Table 3 Annual rates of decline in pre-/post-bronchodilator IC
Tiotropium (mL/year) Cont
N Mean (SE) N
IC
Pre-bronchodilator 2910 36 (3) 2864
Post-bronchodilator 2905 52 (4) 2853
FEV6
Pre-bronchodilator 2910 42 (2) 2864
Post-bronchodilator 2905 57 (2) 2853
SVC
Pre-bronchodilator 2531 47 (3) 2374
Post-bronchodilator 2527 66 (3) 2383
aData from SVC previously published [13].
Abbreviations: FEV6, forced expiratory volume in 6 seconds; IC, inspiratory capacity;there has been no description of the behavior of IC over
long periods of time and of the effect of pharmacologic
therapy on those changes. The measurements of IC and
SVC at baseline and at each of the subsequent visits
were incorporated as part of the standardized spirometry
equipment and software. Such data were envisioned to
help close gaps in knowledge in this important area.
On average, the IC declines over time at a rate that is
similar to the decline in FEV1. This supports the clinical
observation that, as disease progresses, many patients
with COPD will develop hyperinflation. Since the publi-
cation of the study by Fletcher and Peto, it has been
classically stated that the rate of decline of FEV1 in
patients with COPD oscillates around 60 mL/year [6].
Evidence from the UPLIFTW and Towards a Revolution
in COPD Health (TORCH) trials showed that the actual
rate of decline is lower, being on average close to
40 mL/year [13,14]. Furthermore, recent analysis of the
spirometric records of the second Framingham cohort, FEV6, and SVC over 4 years
a
rol (mL/year) Δ Tiotropium–control p-value
Mean (SE) Mean (SE)
32 (3) 5 (5) 0.30
47 (4) 6 (5) 0.28
40 (2) 2 (3) 0.39
57 (2) −0 (3) 0.91
41 (3) 6 (4) 0.11
65 (3) 1 (4) 0.79
SE, standard error; SVC, slow vital capacity.
Table 4 Mean between-treatment differences up to
4 years in pre-bronchodilator IC, SVC, FEV6, and FVC
1 Year 2 Years 3 Years 4 Years
IC (SE) 103 (17) 107 (18) 98 (19) 97 (20)
SVC (SE) 176 (13) 167 (14) 166 (15) 150 (16)
FEV6 (SE) 159 (9) 149 (10) 161 (11) 131 (12)
FVCa (SE) 198 (13) 189 (14) 200 (15) 170 (16)
aData from FVC previously published [13].
Abbreviations: FEV6, forced expiratory volume in 6 seconds; FVC, forced vital
capacity; IC, inspiratory capacity; SE, standard error; SVC, slow vital capacity.
Table 6 All-cause mortality (n [%]) (95 % CI) until Day
1470 according to baseline IC quartiles
IC quartile Tiotropium
(n = 2855)
Control
(n = 2881)
HR (95 % CI)
Q1 141/714 (19.7 %) 158/699 (22.6 %) 0.85 (0.68-1.07)
Q2 115/669 (17.2 %) 136/758 (17.9 %) 0.95 (0.74-1.22)
Q3 94/735 (12.8 %) 104/715 (14.5 %) 0.86 (0.65-1.13)
Q4 64/737 (8.7 %) 78/709 (11.0 %) 0.79 (0.56-1.09)
Abbreviations: CI, confidence interval; HR, hazard ratio; IC, inspiratory capacity.
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decline is approximately 19 mL/year and 30–40 mL for
smokers in that same population. It seems as if the rate
of decline, at least for FEV1, has decreased over the time
that has elapsed since the report by Fletcher and Peto
[6]. It cannot be determined whether this is due to
changes in therapy, the environment, or the anthropo-
metric constitution of populations, but the consequence
is that a ceiling effect may have been reached, beyond
which it will be very difficult to change the rate of de-
cline any further, other than through smoking cessation
in patients who continue to smoke. However, it is theor-
etically possible to attempt to erase the additional rela-
tively small decline that patients with COPD have
compared with non-smoker controls. Interestingly, we
found that the rate of decline of post-bronchodilator IC
was greater in patients with more severe airflow obstruc-
tion (GOLD stage IV, compared with stages III or II).
This finding differs from the pattern observed for FEV1
in the UPLIFTW and TORCH studies, in which there
was a greater decline over time in patients with milder
airflow limitation [13,14].
Even though the rate of decline of IC in UPLIFTW was
similar in patients with tiotropium when compared with
controls, trough IC was larger by approximately 100 mL
in the tiotropium group. These results are consistent
with shorter-term studies with tiotropium [17,18,20,23].
Although we did not measure total lung capacity (TLC),
evidence from shorter-term studies suggests that this
may decrease after bronchodilators, but the decrease is
relatively small, so that the ratio of IC/TLC is likely to
have improved in the patients taking tiotropiumTable 5 Time to first exacerbation (mean months and
HRs) (95 % CI) according to baseline IC quartiles
IC quartile Tiotropium
(n = 2855)
Control
(n = 2881)
HR (95 % CI)
Q1 (n= 1413) 14.3 (11.7-17.0) 10.3 (8.8-11.7) 0.81 (0.72-0.92)
Q2 (n = 1427) 14.7 (12.6-17.6) 10.5 (8.7-12.2) 0.83 (0.73-0.94)
Q3 (n = 1450) 16.8 (13.6-19.8) 14.8 (12.2-17.2) 0.95 (0.83-1.07)
Q4 (n = 1446) 20.4 (17.3-23.4) 15.8 (12.8-18.4) 0.86 (0.75-0.97)
Abbreviations: CI, confidence interval; HR, hazard ratio; IC, inspiratory capacity.compared with those on control [17,20]. The 4-year
UPLIFTW trial substantiated previous reports from trials
up to 1 year in duration, demonstrating that tiotropium
improves exacerbation rates and health-related quality of
life. In addition, the UPLIFTW trial showed that tiotro-
pium could improve survival [13,24]. Such impacts on
the course of COPD are likely to be related to, or at least
influenced by, the change in IC. The data are insufficient
to prove a cause-and-effect relationship, but recent evi-
dence describing a relationship between hyperinflation
and cardiac function, more specifically left ventricular
stroke volume, supports this possible mechanism [25].
Indeed, the data are consistent with a beneficial effect
on cardiac morbidity suggested by the results of the
UPLIFTW and TORCH trials [13,26]. More studies are
needed to explore the impact of changes in lung func-
tion on cardiac physiology.
That the IC findings are real is supported by the meas-
urement of two other volume variables, the FEV6 and,
more importantly, the SVC. It is known that, in patients
with COPD, there is a difference in favor of the vital
capacity between the value obtained with the slow man-
euver and the value obtained during the forced maneu-
ver (i.e. FVC). The SVC in this study was on average
100 mL larger than the FVC in the same patients, con-
firming in a large population what was already known
from smaller physiologic studies. What had not been
explored was the relationship between IC and SVC. In
the current analysis, there was a strong association be-
tween IC and SVC, suggesting that one could potentially
be used as a surrogate marker of the other.
Since we measured both FEV1 and IC in UPLIFT
W, we
sought to determine if both variables changed in tan-
dem, in the same patients and in the same direction, and
whether both variables had a similar prognostic value
for the patient-reported outcomes studied in UPLIFTW.
In relation to the first objective, we observed a close as-
sociation between FEV1 change and IC change, although
the associations between IC and either SVC or FVC
appeared to be stronger. Furthermore, the changes oc-
curred in the same direction in the same patients,
thereby making one variable a potential surrogate mar-
ker of the other. Given the similar strength of their
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single most stable physiologic variable for the study of
these outcomes. UPLIFTW was not designed to answer
the question of the association of IC with exercise cap-
acity and, therefore, this remains to be determined.
There were some limitations to this study. It is pos-
sible that the longitudinal IC changes may have been
affected by the rate of discontinuations in UPLIFTW,
which was approximately 40% overall [13]. However,
similar discontinuation rates have been reported in other
large-scale trials of respiratory maintenance therapies in
COPD [12]. There was no centralized review of the qual-
ity of the IC, although this was undertaken for all slow
and forced expiratory maneuvers that by definition
included the IC. In addition, the large number of
patients and the large number of maneuvers incorpo-
rated reduces the likelihood of variability and random-
ness as an explanation for the results. There are no
validated international predicted values for IC, FEV6,
and SVC, and no information about the minimally clin-
ical important difference, so we had to limit the analyses
to changes in absolute values of these variables. It is un-
likely that expressing these variables as a change in their
predicted values or, in the case of IC, as a change in its
ratio to TLC would have improved the strength of the
analysis or its conclusions.Conclusions
In summary, in patients with GOLD stage II to IV
COPD included in the UPLIFTW study, mean pre- and
post-bronchodilator IC declined from 32 to 36 mL per
year and from 47 to 52 mL per year, respectively. Treat-
ment with tiotropium did not change the rate of decline
of IC over time but provided 24-hour improvements
sustained over the long term. The difference in trough
IC between tiotropium and control suggests that tiotro-
pium resulted in a sustained decrease in EELV. Both IC
and SVC provided information that related to clinical
outcomes, but the close association between changes in
these variables and changes in FEV1 indicates that the
FEV1 remains a relevant physiological variable of use in
the study of patients with COPD. Long-term studies of
the changes in lung volumes and their relation to exer-
cise performance and mortality should be undertaken to
clarify the role of IC and other lung volumes in the rou-
tine management of patients with COPD.
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